The Viladecans facilities of Alcura Health Spain, member of CataloniaBio & HealthTech, obtained the Manufacturer Import Authorization (MIA) granted by the Spanish Agency of Medicines and Medical Devices (AEMPS), which allows the import and release of products associated with gene, cellular, and tissue engineering therapies, also known as ATMP (Advanced Therapy Medicine Products). This authorization makes the Viladecans facilities in Barcelona the first center in the entire international Cencora network to have this authorization. 

The acquisition of this permission paves the way for bringing innovative therapies and precision medicine closer to patients, made possible, among other factors, by Alcura's efforts to strengthen its infrastructure with the incorporation of nitrogen tanks at -196ºC, as well as the reinforcement of the team with highly specialized professionals in advanced therapies. 

According to Josep Oriol Nicolás, Director of Strategic Development at Alcura Health Spain, "with this new authorization, we reinforce our positioning as a disruptive and innovative company in the clinical trial logistics market with an increasingly global reach, focused on offering comprehensive solutions that respond specifically to the needs of any type of patient. This permission not only represents access to new commercial horizons but also an unwavering commitment to quality and safety at the forefront of medical research, crossing borders to offer health solutions that make a difference."